[HTML][HTML] The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

N Guo, JB Liu, W Li, YS Ma, D Fu - Journal of Advanced Research, 2022 - Elsevier
Abstract Background Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
is derived from the bacterial innate immune system and engineered as a robust gene-editing …

Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia

V Profeta, K McIntyre, MK Wells, C Park… - Expert opinion on …, 2023 - Taylor & Francis
Introduction Friedreich ataxia (FRDA) is a rare autosomal recessive degenerative disorder
characterized by ataxia, dysarthria, diabetes, cardiomyopathy, scoliosis, and occasionally …

Rescue of Alzheimer's disease phenotype in a mouse model by transplantation of wild-type hematopoietic stem and progenitor cells

P Mishra, A Silva, J Sharma, J Nguyen, DP Pizzo… - Cell reports, 2023 - cell.com
Alzheimer's disease (AD) is the most prevalent cause of dementia; microglia have been
implicated in AD pathogenesis, but their role is still matter of debate. Our study showed that …

Advantages and limitations of gene therapy and gene editing for Friedreich's ataxia

A Sivakumar, S Cherqui - Frontiers in Genome Editing, 2022 - frontiersin.org
Friedreich's ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by
GAA hyper expansion in intron 1 of frataxin (FXN) gene. This expansion mutation …

Therapy development by genome editing of hematopoietic stem cells

L Koniali, CW Lederer, M Kleanthous - Cells, 2021 - mdpi.com
Accessibility of hematopoietic stem cells (HSCs) for the manipulation and repopulation of the
blood and immune systems has placed them at the forefront of cell and gene therapy …

Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application

S Maheshwari, G Vilema-Enríquez… - Translational …, 2023 - Springer
Friedreich ataxia (FRDA) is a rare genetic multisystem disorder caused by a pathological
GAA trinucleotide repeat expansion in the FXN gene. The numerous drawbacks of historical …

The inherited cerebellar ataxias: an update

G Coarelli, T Wirth, C Tranchant, M Koenig, A Durr… - Journal of …, 2023 - Springer
This narrative review aims at providing an update on the management of inherited
cerebellar ataxias (ICAs), describing main clinical entities, genetic analysis strategies and …

Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model

R Milazzo, A Montepeloso, R Kumar, F Ferro… - Nature …, 2024 - nature.com
The conditions supporting the generation of microglia-like cells in the central nervous
system (CNS) after transplantation of hematopoietic stem/progenitor cells (HSPC) have …

A mutation-agnostic hematopoietic stem cell gene therapy for metachromatic leukodystrophy

JS Antony, A Daniel-Moreno, A Lamsfus-Calle… - The CRISPR …, 2022 - liebertpub.com
Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by mutations in the
Arylsulfatase-A (ARSA) gene. The enzyme plays a key role in sulfatide metabolism in brain …

Removal of the GAA repeat in the heart of a Friedreich's ataxia mouse model using CjCas9

P Yaméogo, C Gérard, N Majeau, JP Tremblay - Gene therapy, 2023 - nature.com
Most Friedreich ataxia (FRDA) cases are caused by the elongation of the GAA repeat (GAAr)
sequence in the first intron of the FXN gene, leading to a decrease of the frataxin protein …